December 02, 2016
3 min watch
Save
This article is more than 5 years old. Information may no longer be current.
VIDEO: Mease discusses effectiveness of tofacitinib against PsA
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
WASHINGTON — At the American College of Rheumatology Annual Meeting, Philip J. Mease, MD, rheumatologist at Swedish Medical Center and clinical professor at the University of Washington, discussed tofacitinib — an oral Janus kinase inhibitor — and its effectiveness against psoriatic arthritis as demonstrated in two studies.
Mease mentioned that both doses of tofacitinib — 5 mg or 10 mg twice per day — were effective in treating all clinical domains. In addition, he said there was evidence of non-progression on radiographs and there were no new adverse events compared with what has been seen in previous studies of tofacitinib against rheumatoid arthritis.